Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

PJP returned 34.6% over the trailing year and grew $1,000 to $1,659 over five years, outperforming RSPH’s 27.0% and $1,310, respectively; PJP also had lower five-year maximum drawdown (17.5% vs. 21.9%) and beta (0.43 vs. 0.78). RSPH offers broader exposure across 61 companies at a 0.40% expense ratio, compared with PJP’s 28 pharmaceutical holdings and 0.58% fee. The article presents RSPH as the diversified option and PJP as the higher-return but more concentrated fund, with exposure to pharma-specific regulatory, trial, and pricing risks.

Analysis

The comparison does not establish that PJP has a durable edge: trailing outperformance may reflect a favorable pharma factor regime, while backward-looking beta and drawdown can understate discontinuous risks from trial outcomes, patent exposure, or pricing policy. The key exposure is not simply “concentrated versus diversified”: PJP is more sensitive to pharma-specific earnings revisions and drug-cycle leadership; RSPH dilutes that exposure but its equal weighting can leave it more exposed to weaker or smaller constituents and rebalance effects. The cited GLP-1 theme is not enough to underwrite PJP—verify current holdings and weights, since the leaders of a theme need not be material contributors to this ETF.

Near term, there is no compelling directional trade from the supplied data alone. Over 1–3 months, relative returns will likely hinge on pharma earnings revisions, policy headlines, and pipeline news; over 6–18 months, patent erosion and replacement-product launches matter more than the funds’ fee gap. The 18bp annual fee difference is secondary to constituent returns, turnover, and trading spreads. A low historical beta is not protection against event gaps. The contrarian risk is chasing PJP’s realized performance just as its underlying leadership reverses; conversely, a broad-sector allocation could lag if pharma momentum and earnings estimates continue to strengthen.

Key Decisions for Investors

• Do not buy PJP solely on trailing performance or the GLP-1 narrative. Before sizing, verify current holdings, concentration, turnover, and constituent earnings-revision breadth; also compare bid-ask spreads and underlying liquidity.
• For a diversified healthcare allocation, use RSPH as the more balanced expression, but do not assume equal weighting eliminates risk: monitor breadth and whether its smaller constituents are contributing or detracting.
• Watchlist, not an immediate recommendation: consider a dollar- or beta-adjusted long RSPH/short PJP relative-value position only if pharma earnings revisions weaken while broader healthcare breadth improves. Reassess or exit if pharma revisions reaccelerate, or if RSPH breadth deteriorates; establish sizing only after measuring current factor exposures and volatility.
• Key falsifiers and catalysts: a material change in drug-pricing policy, adverse trial readouts or patent-loss developments, and the next round of constituent guidance. No price target or quantified relative-value risk/reward is supportable without current valuations, fund holdings, flows, and forward estimate data.